Tempest Therapeutics (TPST) Short term Debt (2017 - 2025)
Tempest Therapeutics (TPST) posted Short term Debt of $4.2 million for Q1 2025, down 34.06% sequentially from $6.4 million in Q4 2024, and down 35.12% YoY from $6.5 million in Q1 2024.
Tempest Therapeutics (TPST) Short term Debt (2017 - 2025) Analysis & Trends
Tempest Therapeutics has reported Short term Debt for 8 years, with the latest figure at $4.2 million in Q1 2025.
- Quarterly Short term Debt fell 35.12% year-over-year to $4.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $4.2 million (down 35.12% YoY) and the FY2024 annual result came in at $6.4 million, up 48.28% from the prior year.
- Short term Debt fell to $4.2 million in Q1 2025 per TPST's latest filing, from $6.4 million in the prior quarter.
- Over five years, Short term Debt peaked at $8.6 million in Q2 2024 and troughed at $235000.0 in Q1 2021.
- A 4-year average of $4.5 million and a median of $4.2 million in 2023 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2024 and 2025: Short term Debt surged 336.06% in 2024, then slumped 35.12% in 2025.
- Over 4 years, Short term Debt stood at $235000.0 in 2021, then jumped by 1723.4% to $4.3 million in 2023, then soared by 48.28% to $6.4 million in 2024, then tumbled by 34.06% to $4.2 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods registered $4.2 million, $6.4 million, and $8.5 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 4.19 Mn |
| Dec 31, 2024 | 6.35 Mn |
| Sep 30, 2024 | 8.50 Mn |
| Jun 30, 2024 | 8.65 Mn |
| Mar 31, 2024 | 6.46 Mn |
| Dec 31, 2023 | 4.29 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.97 Mn |
| Mar 31, 2023 | 1.48 Mn |
| Mar 31, 2021 | 235,000.00 |
| Dec 31, 2020 | 239,000.00 |
| Sep 30, 2020 | 222,000.00 |
| Jun 30, 2020 | 207,000.00 |
| Mar 31, 2020 | 258,000.00 |
| Dec 31, 2019 | 208,000.00 |
| Sep 30, 2019 | 197,000.00 |
| Jun 30, 2019 | 199,000.00 |
| Mar 31, 2019 | 191,000.00 |
| Dec 31, 2018 | 189,000.00 |
| Dec 31, 2017 | 174,000.00 |